Primary Open Angle Glaucoma (POAG)

1. Clinical Overview

Summary

Primary Open Angle Glaucoma (POAG) is a chronic, progressive optic neuropathy characterized by selective degeneration of retinal ganglion cells, leading to characteristic Optic Disc Cupping and corresponding Visual Field defects. It is traditionally associated with raised Intraocular Pressure (IOP >21mmHg), although Normal Tension Glaucoma (NTG) exists where optic nerve damage occurs despite statistically normal IOP. [1,2]

POAG is the leading cause of irreversible blindness worldwide, affecting approximately 70 million people globally. The condition is aptly termed "The Silent Thief of Sight" because it typically remains asymptomatic until advanced stages, destroying peripheral vision insidiously before patients become aware of visual loss. By the time symptoms are noticed, up to 40% of retinal ganglion cells may already be lost. [3,4]

The term "open angle" distinguishes this condition from angle-closure glaucoma by referring to the configuration of the anterior chamber angle—the anatomical region between the peripheral iris and the trabecular meshwork where aqueous humor drains from the eye. In POAG, this angle remains anatomically open on gonioscopy, yet resistance to aqueous outflow is pathologically increased due to dysfunction at the cellular level within the trabecular meshwork and Schlemm's canal. [5]

Key Facts

• Mechanism: Increased resistance to outflow of aqueous humor through the Trabecular Meshwork (TM), not physical obstruction. The pathophysiology involves extracellular matrix remodeling, endothelial cell dysfunction in Schlemm's canal, and reduced cellularity of the TM. [6]

• The Turning Point (LiGHT Trial): Historically, topical medications (eye drops) were considered first-line therapy. The landmark LiGHT trial (Lancet 2019) demonstrated that Selective Laser Trabeculoplasty (SLT) provides superior clinical outcomes, better quality of life, and is more cost-effective than initial medical therapy. This led to the NICE guidelines (2022 update) recommending SLT as first-line treatment for newly diagnosed POAG and ocular hypertension. [7]

• Corneal Thickness: Central Corneal Thickness (CCT) significantly affects IOP measurement accuracy. Thicker corneas (>555 μm) artificially increase Goldmann applanation tonometry readings, potentially leading to overdiagnosis of ocular hypertension. Conversely, thin corneas (less than 500 μm) underestimate true IOP and represent an independent risk factor for glaucoma development. The Ocular Hypertension Treatment Study (OHTS) identified CCT as one of the strongest predictive factors for conversion from ocular hypertension to glaucoma. [8,9]

• Target IOP: Treatment aims to achieve a "target IOP"—typically a 20-30% reduction from baseline untreated pressure. This target is individualized based on severity of damage, rate of progression, and life expectancy. Lower targets (often less than 15 mmHg) are set for advanced disease or rapidly progressing glaucoma. [10]

Clinical Pearls

The Optic Disc "Cup": The optic cup is the central pale area within the optic disc, representing the absence of neural tissue. The neuroretinal rim is the peripheral pink/orange tissue containing the retinal ganglion cell axons. In glaucoma, progressive loss of axons causes the rim to thin and the cup to expand. The ISNT rule describes the normal pattern of rim thickness: Inferior > Superior > Nasal > Temporal. Glaucomatous damage typically violates this rule, with preferential loss in the inferior and superior regions (corresponding to the arcuate nerve fiber bundles), leading to vertical elongation of the cup. [11]

Asymmetry is Key: A cup-to-disc (C:D) ratio difference >0.2 between eyes is highly suspicious for glaucoma, even if absolute values seem within normal range. Progressive enlargement of the cup over time (documented photographically or with OCT) is more diagnostic than a single measurement.

Don't Wait for Symptoms: By the time a patient reports "tunnel vision," they have already lost approximately 90% of their optic nerve fibers. Central vision (20/20 Snellen acuity) can remain excellent until end-stage disease. Early diagnosis relies entirely on screening through routine optometric examinations and opportunistic case-finding in at-risk populations.

Systemic Absorption of Topical Medications: Topical beta-blockers (timolol, levobunolol) are absorbed systemically via the nasolacrimal duct and nasal mucosa, achieving plasma concentrations comparable to oral administration. This can precipitate life-threatening bronchospasm in asthmatics or severe bradycardia/heart block in susceptible patients. Always check for contraindications and advise punctal occlusion technique to minimize systemic absorption. [12]

Glaucoma "Suspects": Many patients are labeled as "glaucoma suspects"—individuals with one or more risk factors (elevated IOP, large C:D ratio, positive family history) but no definitive evidence of glaucomatous damage. These patients require regular monitoring but not necessarily immediate treatment. The decision to treat is based on risk stratification.

---

2. Epidemiology

Global Burden

POAG is the most common form of glaucoma worldwide, accounting for approximately 74% of all glaucoma cases. Global prevalence estimates indicate that POAG affects approximately 68 million individuals, with projections suggesting this will increase to 111.8 million by 2040 due to aging populations. [3,13]

Age Distribution

• Prevalence increases exponentially with age
• Affects approximately 2% of the population over age 40
• Rises to 10-15% in those over 80 years
• Rare before age 40 (juvenile-onset POAG represents less than 5% of cases)
• Mean age at diagnosis: 60-65 years [14]

Ethnic Variations

Significant ethnic disparities exist in POAG prevalence, severity, and age of onset:

• Black African/Caribbean: 4-6 times higher prevalence than European populations, with earlier onset (often presenting in the 40s), more aggressive disease progression, and higher rates of blindness. The Barbados Eye Study demonstrated POAG prevalence of 7% in Black populations vs. 1.1% in White populations. [15,16]

• Hispanic/Latino: 2-3 times higher risk than non-Hispanic Whites, particularly in Mexican-American populations. [17]

• Asian Populations: Lower prevalence of POAG (1-3%) but higher prevalence of angle-closure glaucoma. Normal-tension glaucoma is particularly common in Japanese populations, representing up to 90% of POAG cases in some studies. [18]

• European/Caucasian: Baseline prevalence approximately 2-3% over age 40.

Sex Distribution

• Slightly more common in men (male-to-female ratio approximately 1.4:1)
• However, women represent the majority of blind individuals due to longer life expectancy [14]

Genetic Factors

POAG demonstrates clear genetic predisposition:

• Family History: First-degree relatives have a 10-fold increased risk
• Heritability: Twin studies suggest heritability of 50-70%
• Genetic Loci: Multiple genes implicated, including:
  • "MYOC (Myocilin): 3-5% of POAG cases, typically early-onset, severe phenotype"
  • "OPTN (Optineurin): Associated with normal-tension glaucoma"
  • "TBK1, WDR36, NTF4: Various associations with POAG subtypes"
• Genome-wide association studies (GWAS) have identified >100 genetic loci associated with POAG, collectively explaining approximately 50% of disease heritability [19,20]

Risk Factors

Non-modifiable:

• Advanced age (strongest risk factor)
• African/Hispanic ethnicity
• Family history of glaucoma
• Thin central corneal thickness (less than 500 μm)
• Large cup-to-disc ratio (>0.5)
• Myopia (especially high myopia >-6.00 D)

Modifiable/Associated:

• Elevated intraocular pressure (strongest modifiable risk factor)
• Diabetes mellitus (controversial—some studies show increased risk)
• Systemic hypertension (may increase IOP but also perfusion pressure)
• Cardiovascular disease
• Nocturnal hypotension (especially relevant in NTG)
• Obstructive sleep apnea
• Migraine/vasospastic disorders (particularly in NTG)
• Corticosteroid use (steroid-induced IOP elevation) [8,21,22]

Ocular Risk Factors

• High intraocular pressure (>21 mmHg)
• Low corneal hysteresis (biomechanical property of cornea)
• Larger optic disc area (allows more "room" for cupping)
• Disc hemorrhages (splinter hemorrhages at disc margin)
• Pseudoexfoliation syndrome
• Pigment dispersion syndrome
• Prior ocular trauma or inflammation

---

3. Pathophysiology

Aqueous Humor Dynamics

Understanding POAG requires knowledge of aqueous humor production, circulation, and drainage:

1. Production (2.5-3.0 μL/min)

• Site: Ciliary body epithelium (non-pigmented epithelium)
• Mechanism: Active secretion (60%), ultrafiltration (30%), diffusion (10%)
• Regulation: Carbonic anhydrase-dependent, adrenergic-mediated
• Circadian variation: Production peaks in morning, decreases during sleep (explaining why IOP is typically highest in early morning) [23]

2. Circulation

• Posterior chamber → through pupil → anterior chamber
• Provides nutrients to avascular structures (lens, corneal endothelium)
• Maintains intraocular pressure
• Removes metabolic waste products

3. Drainage (must equal production to maintain stable IOP)

A. Conventional (Trabecular) Pathway (80-90%):

• Aqueous flows through the trabecular meshwork (TM)
• Three distinct regions:
  • "Uveal meshwork: Innermost, largest pores"
  • "Corneoscleral meshwork: Middle layer"
  • "Juxtacanalicular tissue (JCT): Outermost layer, provides majority of outflow resistance"
• Fluid enters Schlemm's canal (analogous to lymphatic vessel)
• Collector channels drain to episcleral veins
• Primary site of pathology in POAG: Increased resistance at JCT level [24]

B. Unconventional (Uveoscleral) Pathway (10-20%):

• Pressure-independent flow
• Through ciliary muscle face → suprachoroidal space → transscleral or orbital route
• Enhanced by prostaglandin analogs (mechanism of latanoprost, bimatoprost) [25]

Pathological Mechanisms in POAG

Trabecular Meshwork Dysfunction

The fundamental defect in POAG is increased outflow resistance, primarily at the juxtacanalicular tissue and inner wall of Schlemm's canal:

1. Cellular Changes:

   • Decreased TM cellularity (age-related loss accelerated in POAG)
   • Endothelial dysfunction in Schlemm's canal
   • Loss of trabecular beams (particularly in pigment dispersion syndrome)
   • Abnormal cell-matrix interactions [6]

2. Extracellular Matrix Alterations:

   • Accumulation of abnormal extracellular matrix material
   • Increased collagen deposition
   • Changes in glycosaminoglycan composition
   • Cross-linking of matrix proteins (reducing "permeability")
   • In MYOC-related glaucoma: Myocilin protein accumulates in TM [26]

3. Oxidative Stress:

   • Increased reactive oxygen species (ROS) in TM
   • Mitochondrial dysfunction
   • Reduced antioxidant capacity
   • Age-related accumulation of damaged proteins [27]

4. Impaired Phagocytic Function:

   • TM cells normally phagocytose debris and clear cellular waste
   • This function declines with age and is impaired in POAG
   • Accumulation of pigment, proteins, and cellular debris

Optic Nerve Head Biomechanics

The optic nerve head (ONH) is the primary site of damage in glaucoma:

1. Lamina Cribrosa:

   • Collagenous structure through which retinal ganglion cell axons exit the eye
   • Mechanical Theory: IOP-related stress causes posterior bowing and compression of laminar beams, disrupting axoplasmic transport in ganglion cell axons [28]
   • Remodeling: Chronic stress leads to extracellular matrix remodeling, further weakening the structure
   • Individual susceptibility varies based on laminar thickness, beam density, and collagen composition

2. Vascular Dysregulation Theory:

   • Perfusion pressure = Mean arterial pressure - IOP
   • Compromised blood flow to ONH (particularly nocturnal dips in blood pressure)
   • Especially relevant in normal-tension glaucoma
   • Endothelin-1 (vasoconstrictor) levels elevated in glaucoma patients
   • Autoregulatory dysfunction in optic nerve head vasculature [29]

3. Astrocyte Activation:

   • Astrocytes at the ONH respond to mechanical stress and ischemia
   • Reactive gliosis produces neurotoxic factors
   • Abnormal extracellular matrix production
   • May contribute to "secondary" neurodegeneration

Retinal Ganglion Cell Death

The hallmark of glaucoma is progressive, irreversible loss of retinal ganglion cells (RGCs):

1. Apoptotic Pathway:

   • Intrinsic (mitochondrial) apoptosis pathway activated
   • Caspase-mediated cell death
   • "Point of no return" even if IOP normalized [30]

2. Axoplasmic Transport Blockade:

   • Compression at lamina cribrosa blocks anterograde and retrograde axoplasmic flow
   • Deprivation of neurotrophic factors (BDNF, NGF)
   • Accumulation of cellular waste products
   • Mitochondrial dysfunction

3. Excitotoxicity:

   • Glutamate-mediated excitotoxicity
   • NMDA receptor overstimulation
   • Calcium influx and cell death

4. Immune-Mediated Mechanisms:

   • Emerging evidence of autoimmune component
   • Anti-retinal antibodies identified in some patients
   • Microglial activation and neuroinflammation [31]

5. Trans-synaptic Degeneration:

   • Death of RGCs leads to retrograde degeneration
   • Lateral geniculate nucleus thinning
   • Visual cortex atrophy (detectable on MRI in advanced cases)

Visual Field Defects: Anatomical Correlation

The pattern of visual field loss reflects the anatomy of the retinal nerve fiber layer:

• Arcuate Scotomas: Loss along the arcuate bundles (superior and inferior)
• Nasal Step (Roelofs sign): Sharp demarcation at horizontal raphe
• Temporal Wedge: Corresponding to nasal nerve fibers
• Central Island: Sparing of fixation until late disease (papillomacular bundle relatively resistant)
• Temporal Crescent: Last remaining field in end-stage disease [32]

The inferior and superior poles of the optic disc (where arcuate fibers enter) are most vulnerable, possibly due to:

• Greater mechanical stress at these regions
• Watershed zones of vascular supply
• Thinner lamina cribrosa in these areas

---

4. Clinical Presentation

Symptoms

Early-Stage POAG

• Completely Asymptomatic in >90% of cases
• Detected incidentally during routine optometry examination
• May be identified through workplace vision screening or driving license renewal testing
• Patient has no awareness of peripheral field loss due to:
  • Gradual onset (adaptation)
  • Binocular compensation
  • Filling-in by visual cortex

Moderate-Stage POAG

• Subtle Functional Impairment:
  • Difficulty with dark adaptation
  • Bumping into objects on peripheral side
  • Near-misses while driving (not seeing cars in adjacent lanes)
  • Difficulty navigating crowded spaces
  • Tripping over curbs or missing steps on stairs
  • Reading difficulties (need to move head more to see full line)
• Patients may attribute symptoms to "getting older" or "needing new glasses"

Advanced-Stage POAG

• "Tunnel Vision":
  • Severe constriction of peripheral visual field
  • Remaining "island" of central vision
  • Difficulty with mobility and activities of daily living
  • Unable to see people approaching from the side
  • Significant disability
• Central Vision Loss (end-stage):
  • Loss of reading vision
  • Profound visual impairment
  • Registration as blind (visual acuity less than 6/60 or field less than 20° in better eye)

Presentation Patterns

• Screening Detection (most common): Identified at optometrist visit with:

  • Elevated IOP on non-contact tonometry
  • Suspicious optic disc appearance
  • Abnormal OCT retinal nerve fiber layer

• Optometrist Referral: Formal "glaucoma suspect" referral to ophthalmology with supporting visual fields and imaging

• Incidental Finding: Detected during evaluation for other ocular complaint (cataract, refractive error)

• Symptomatic Presentation (late-stage): Patient reports visual field loss or difficulty with daily activities

• Trauma to Blind Eye: Unfortunately, some cases present after trauma to what the patient thought was their "good eye," only to discover the fellow eye was already blind from undiagnosed glaucoma

Physical Signs

Intraocular Pressure

• Normal IOP: 10-21 mmHg (population mean: 15-16 mmHg)
• Glaucomatous IOP: Typically >21 mmHg, but significant overlap exists
  • ~30-50% of POAG patients have IOP >21 mmHg at time of diagnosis
  • "Normal-Tension Glaucoma: IOP consistently less than 21 mmHg despite glaucomatous damage"
  • "Ocular Hypertension: IOP >21 mmHg without optic nerve damage or field loss"
• Diurnal Variation: IOP fluctuates throughout day (typically highest in morning)
• Risk increases continuously: No "safe" IOP; each 1 mmHg increase in IOP increases risk by ~10% [33]

Optic Disc Changes (Fundoscopy/Slit-lamp Biomicroscopy)

Cup-to-Disc Ratio (C:D Ratio):

• Horizontal measurement of cup diameter / disc diameter
• Normal: 0.1-0.4 (wide population variation; larger discs have larger cups)
• Glaucoma suspect: >0.5 or asymmetry >0.2 between eyes
• Advanced glaucoma: >0.8 ("bean-pot" cupping)

ISNT Rule Violation:

• Normal rim configuration: Inferior > Superior > Nasal > Temporal
• Glaucoma violates this rule (preferential inferior/superior thinning)

Focal Notching:

• Localized rim loss (especially inferotemporal and superotemporal)
• Highly specific for glaucoma
• Corresponds to visual field defect in same quadrant

Disc Hemorrhages (Splinter Hemorrhages):

• Small flame-shaped hemorrhages at disc margin
• Marker of active disease progression
• Associated with worse prognosis
• Found in 4-7% of POAG patients at any given time (transient—may disappear in weeks)
• Drance hemorrhage: Named after S.M. Drance who first described their significance [34]

Bayonetting of Vessels:

• Vessel "kinking" as they pass over edge of enlarged cup
• Occurs as cup deepens posteriorly

Laminar Dots:

• Visible fenestrations in lamina cribrosa at base of deep cup

Peripapillary Atrophy:

• Zone alpha (peripheral): Hyper/hypopigmentation
• Zone beta (adjacent to disc): Visible sclera and choroidal vessels
• Beta zone associated with glaucoma progression

Nasalization of Vessels:

• Shift of central retinal vessels toward nasal side of disc

Anterior Segment Examination

Gonioscopy (ESSENTIAL for diagnosis):

• Direct visualization of anterior chamber angle using mirrored lens (Goldmann, Zeiss)
• Shaffer Grading System (angle width):
  • "Grade 4: Wide open (35-45°) - normal"
  • "Grade 3: Open (25-35°) - normal"
  • "Grade 2: Narrow (20°) - appositional closure possible"
  • "Grade 1: Very narrow (10°) - high risk"
  • "Grade 0: Closed - angle closure"
• In POAG: Angle is open (typically grade 3-4) with visible structures:
  • Schwalbe's line (transition from cornea to TM)
  • Trabecular meshwork (pigmented band)
  • Scleral spur
  • Ciliary body band
• Pigmentation: Increased TM pigmentation may indicate previous pigment dispersion or pseudoexfoliation

Anterior Chamber:

• Deep (normal depth)
• Quiet (no inflammation—distinguishes from uveitic glaucoma)

Cornea:

• Measure Central Corneal Thickness (CCT) with pachymetry
• Assess for signs of previous trauma, inflammation, or corneal dystrophy

Visual Field Defects (Perimetry)

Early Changes:

• Paracentral Scotomas: Small defects within 10° of fixation
• Nasal Step (Roelofs sign): Defect respecting horizontal meridian
• Arcuate Scotoma: Curving defect following nerve fiber layer (Bjerrum's area, 10-20° from fixation)
• Increased variability in sensitivity

Moderate Changes:

• Enlargement and deepening of arcuate defects
• Connection of scotomas ("ring scotoma")
• Significant superior or inferior field loss

Advanced Changes:

• Tunnel Vision: Severe peripheral constriction with small central island
• Temporal Island: Last remaining peripheral field
• Central Island: Sparing of central 5-10° of fixation
• End-stage: Complete loss except small temporal or central remnant

Patterns:

• Superior field defects more common than inferior (inferior disc more vulnerable)
• Progression typically faster in superior field

---

5. Clinical Examination

A comprehensive glaucoma evaluation includes the following components:

History

Ocular History:

• Previous eye examinations (dates, findings)
• Prior IOP measurements
• Family history of glaucoma (siblings, parents—autosomal dominant inheritance patterns)
• Previous eye trauma, surgery, inflammation
• Contact lens wear
• Refractive error (myopia is risk factor)

Medical History:

• Systemic hypertension or hypotension
• Diabetes mellitus
• Migraine or vasospastic disorders (Raynaud's)
• Cardiovascular disease
• Obstructive sleep apnea
• Thyroid disease
• Steroid use (oral, inhaled, topical, intra-articular)

Medication History:

• Current glaucoma medications (compliance, timing, side effects)
• Systemic beta-blockers (may mask IOP-lowering effect of topical beta-blockers)
• Anticholinergic medications
• Topical or systemic steroids

Social History:

• Occupation (visual demands)
• Driving status
• Impact on activities of daily living

Visual Acuity

• Distance and near acuity
• With current correction
• Pinhole acuity if reduced (to detect refractive error)
• Important: POAG does not reduce visual acuity until very late (unlike cataracts or macular degeneration)

Pupil Examination

• Assess for relative afferent pupillary defect (RAPD)
• RAPD indicates asymmetric optic nerve disease
• Graded using swinging flashlight test (0.3-0.9 log units)
• Significant RAPD suggests substantial asymmetric damage

Intraocular Pressure Measurement (Tonometry)

Goldmann Applanation Tonometry (GAT):

• Gold Standard for IOP measurement
• Principle: Force required to flatten (applanate) 3.06 mm diameter area of cornea
• Performed at slit lamp after topical anesthetic (proxymetacaine) and fluorescein
• Record measurement to nearest 1 mmHg
• Sources of Error:
  • "Thick corneas: Overestimate IOP (add ~2-4 mmHg per 50 μm above average)"
  • "Thin corneas: Underestimate IOP (subtract ~2-4 mmHg per 50 μm below average)"
  • "High astigmatism (>3D): Measure along two meridians"
  • "Excessive fluorescein: Wide, thick rings (overestimation)"
  • "Valsalva, breath-holding, tight collar: Elevate IOP transiently [35]"

Non-Contact Tonometry (Air-Puff):

• Screening tool only (less accurate)
• No corneal contact required
• Useful for children or anxious patients
• Requires confirmation with GAT if abnormal

Other Methods:

• Rebound Tonometry (iCare): Portable, useful in children
• Dynamic Contour Tonometry: Less affected by CCT
• Ocular Response Analyzer: Measures corneal hysteresis (biomechanical property)

Diurnal IOP Measurement:

• Phased testing: Multiple measurements throughout day
• Identifies peak IOP (often missed on single measurement)
• Useful in "normal-tension" glaucoma suspects
• Typical pattern: Highest in morning (7-9 AM), lower in afternoon/evening

Gonioscopy

• Essential to distinguish open-angle from angle-closure glaucoma
• Performed with indirect goniolenses:
  • "Goldmann 3-mirror lens: Requires coupling gel, provides magnified view"
  • "Zeiss 4-mirror lens: No gel required, but may inadvertently indent cornea"
• Assess all 360° of angle
• Document grading (Shaffer system), pigmentation, peripheral anterior synechiae, abnormal vessels, angle recession
• Dynamic gonioscopy: Indentation to distinguish appositional from synechial closure

Central Corneal Thickness (Pachymetry)

• Normal CCT: 540 ± 30 μm (population average ~545 μm)
• Measured with ultrasound pachymeter or OCT
• Thin CCT (less than 500 μm):
  • Underestimates true IOP
  • Independent risk factor for glaucoma
  • Associated with faster progression
• Thick CCT (>590 μm):
  • Overestimates IOP
  • May lead to misdiagnosis of ocular hypertension
• OHTS data: Each 40 μm thinner CCT associated with 71% increased risk of developing POAG [8]

Optic Disc Assessment

Methods:

• Direct Ophthalmoscopy: Limited view, no stereopsis
• Slit-Lamp Biomicroscopy (with 78D, 90D lens): Magnified, stereoscopic view—preferred
• Fundus Photography: Document baseline and track changes
• Optical Coherence Tomography (OCT): Quantitative neuroretinal rim analysis

Assessment Parameters:

• Cup-to-disc ratio (vertical and horizontal)
• Neuroretinal rim contour (ISNT rule)
• Disc size (larger discs have larger cups normally)
• Focal notching
• Disc hemorrhages
• Peripapillary atrophy
• Retinal nerve fiber layer defects (wedge-shaped dark areas)

Retinal Nerve Fiber Layer (RNFL) Examination

• Red-Free (Green) Light Photography: Enhances visibility of RNFL
• OCT: Quantitative measurement of RNFL thickness
  • "Normal: 90-110 μm (average global RNFL)"
  • "Glaucoma suspect: less than 85 μm or significant asymmetry"
  • Thinning detectable years before visual field loss
  • Compare to normative database (age-matched)
  • Superior and inferior quadrants typically affected first

Visual Field Testing (Perimetry)

Standard Automated Perimetry (SAP):

• Humphrey Field Analyzer: Most widely used
  • "24-2 or 30-2 SITA-Standard protocol: Tests central 24° or 30°"
  • 6-8 minutes per eye
  • Plots threshold sensitivity at each point
• Interpretation:
  • "Global Indices:"
    • MD (Mean Deviation): Average deviation from age-matched normal (negative = field loss)
    • PSD (Pattern Standard Deviation): Irregularity of field (elevated in localized loss)
    • VFI (Visual Field Index): Percentage of normal field (100% = normal, 0% = complete loss)
  • "Probability Plots: Statistical significance of defects"
  • "Glaucoma Hemifield Test (GHT): Compares superior and inferior hemifields"
• Progression Analysis: Compare serial fields over time (minimum 5 fields for reliable trend)
  • "Guided Progression Analysis (GPA): Flags likely progression"

Frequency-Doubling Technology (FDT):

• Screens for early glaucomatous damage
• Faster than SAP (5 minutes)
• Detects magnocellular pathway dysfunction

Goldmann Perimetry (Kinetic):

• Manual plotting by technician
• Useful in patients unable to perform automated testing
• Maps isopters (boundaries of equal sensitivity)

Optical Coherence Tomography (OCT)

Spectral-Domain OCT (SD-OCT):

• Non-invasive, cross-sectional imaging
• Resolution 3-7 μm
• Scans in seconds

Parameters Measured:

1. RNFL Thickness:

   • Global average and quadrant analysis
   • Comparison to normative database (color-coded: green = normal, yellow = borderline, red = abnormal)
   • Clock-hour analysis (12 sectors around disc)
   • Detects change earlier than visual fields (structural precedes functional loss)

2. Optic Nerve Head Analysis:

   • Rim area, disc area, cup volume
   • Cup-to-disc ratio (automated measurement)
   • RNFL deviation map

3. Ganglion Cell Complex (GCC) Analysis:

   • Measures macular ganglion cell layer + inner plexiform layer
   • Alternative to RNFL analysis
   • Less affected by disc anomalies or high myopia

Progression Detection:

• Trend Analysis: Linear regression of RNFL thickness over time
• Event Analysis: Significant deviation from baseline
• Requires serial imaging (every 6-12 months)

Ancillary Imaging

Heidelberg Retinal Tomography (HRT):

• Confocal scanning laser ophthalmoscopy
• Creates 3D topographic map of optic disc
• Less commonly used now (superseded by OCT)

Fundus Photography:

• Stereo disc photos (gold standard for documentation)
• Wide-field imaging
• Track disc hemorrhages and structural changes

---

6. Investigations

Diagnostic Tests

1. Visual Field Testing (Perimetry)

See detailed description in Clinical Examination section above.

• Baseline: Two reliable fields to establish baseline (reduce learning effect)
• Follow-up: Every 6-12 months depending on risk and stability
• Criteria for Progression:
  • GPA showing "likely progression" on 3 consecutive tests
  • Sustained decline in MD >2 dB
  • Expansion of scotoma depth or area

Reliability Indices (Humphrey):

• Fixation losses: Should be less than 20% (indicates patient maintained fixation)
• False positives: Should be less than 15% (patient not trigger-happy)
• False negatives: Should be less than 20% (patient not fatigued or inattentive)

2. Optical Coherence Tomography (OCT)

• Frequency: Baseline and every 6-12 months
• Uses:
  • Detect structural damage before visual field loss
  • Monitor progression
  • Differentiate glaucoma from other optic neuropathies
• Limitations:
  • Cannot detect loss in areas with pre-existing RNFL thinning
  • "Floor effect": Once RNFL less than 50 μm, further loss difficult to detect
  • Media opacity (cataracts) reduces image quality

3. Pachymetry (Central Corneal Thickness)

• Single baseline measurement usually sufficient (CCT doesn't change significantly)
• Used to interpret IOP measurements
• Risk stratification

4. Gonioscopy

• Baseline: Essential to confirm open angle
• Re-evaluation: If clinical suspicion of angle narrowing, trauma, or new symptoms

5. Diurnal IOP Curve (Phased Testing)

• Indications:
  • Suspected normal-tension glaucoma with single normal IOP
  • Unexplained progression despite apparently controlled IOP
  • High-risk patients
• Protocol: IOP measured 4-6 times throughout day (e.g., 8 AM, 10 AM, 12 PM, 2 PM, 4 PM)
• Interpretation: Peak IOP, fluctuation (range), nocturnal considerations

6. Blood Pressure Measurement

• Assess for systemic hypertension or hypotension
• Calculate ocular perfusion pressure (OPP):
  • OPP = 2/3 × [DBP + 1/3(SBP - DBP)] - IOP
  • Low OPP (less than 50 mmHg) associated with glaucoma risk and progression
• Consider 24-hour ambulatory BP monitoring if NTG suspected (nocturnal dipping)

Risk Calculators and Staging

Ocular Hypertension Treatment Study (OHTS) Risk Calculator:

• Predicts 5-year risk of conversion from OHT to POAG
• Variables: Age, IOP, CCT, vertical C:D ratio, PSD
• Available online: Risk score 0-30%+
• Helps decide whether to treat ocular hypertension [8]

Glaucoma Severity Staging (Modified Hodapp-Parrish-Anderson):

• Early: MD better than -6 dB
• Moderate: MD between -6 and -12 dB
• Advanced: MD worse than -12 dB or significant central field loss
• OR based on VFI: Early >90%, Moderate 70-90%, Advanced less than 70%

Alternative Staging (Based on structural and functional loss):

• Stage 0 (Suspect): Risk factors but no confirmed damage
• Stage 1: Early optic disc or RNFL changes, minimal field loss
• Stage 2: Moderate disc cupping and field defects
• Stage 3: Advanced cupping, significant field loss
• Stage 4: Severe damage, threat to central fixation
• Stage 5: End-stage, loss of central fixation

---

7. Management

The fundamental goal of glaucoma management is to preserve vision and quality of life by slowing or halting progression of optic nerve damage. Since lost vision cannot be recovered, all treatment is preventative.

Management Principles

1. Lower IOP: The only proven modifiable risk factor
2. Set Target IOP: Individualized based on severity, progression rate, life expectancy
3. Monitor Progression: Regular visual fields and imaging
4. Adjust Treatment: If progression detected despite therapy
5. Shared Decision-Making: Involve patient in treatment choice (drops vs. laser vs. surgery)
6. Maximize Adherence: Simplify regimen, minimize side effects, patient education

Target IOP Setting

Collaborative Normal-Tension Glaucoma Study (CNTGS) and Advanced Glaucoma Intervention Study (AGIS) provide evidence for target IOP:

• General Rule: 20-30% reduction from baseline untreated IOP
• Early Disease, Low Risk: Target less than 21 mmHg or 20% reduction
• Moderate Disease or Risk Factors: Target less than 18 mmHg or 25% reduction
• Advanced Disease or Rapid Progression: Target less than 15 mmHg or 30% reduction (may need less than 12 mmHg)
• Monocular (One-Eyed) Patient: Aggressive target (may need surgical intervention early)

Adjust Target If:

• Disease progresses despite achieving target (lower target needed)
• Patient experiences treatment side effects (may accept higher target if mild disease)
• Advanced age, limited life expectancy (balance risk-benefit)

---

8. Treatment Modalities

First-Line: Laser Trabeculoplasty

Selective Laser Trabeculoplasty (SLT)

Mechanism:

• 532 nm frequency-doubled Nd:YAG laser (Q-switched, nanosecond pulses)
• Targets pigmented trabecular meshwork cells selectively (spares non-pigmented cells)
• Induces biological response: cytokine release, macrophage recruitment, cellular repopulation
• Remodels extracellular matrix in TM
• Reduces outflow resistance [36]

Evidence (LiGHT Trial):

• Multicenter RCT: SLT vs. topical medication (latanoprost) as first-line
• Results (3-year follow-up):
  • Better IOP control with SLT
  • "Lower progression rate: 11.4% (SLT) vs. 19.5% (drops)"
  • 93% of SLT group avoided drops at 3 years
  • Superior quality of life (no daily drop burden)
  • Cost-effective (savings of £500-700 per patient over 3 years)
• Impact: NICE NG81 (updated 2022) now recommends SLT as first-line for newly diagnosed POAG/OHT [7]

Procedure:

• Outpatient office procedure (5-10 minutes)
• Topical anesthetic eye drops
• Goniolens (Latina SLT lens or similar) to visualize angle
• 50-100 laser spots applied to 180° or 360° of TM
• Post-procedure: Topical anti-inflammatory (ketorolac or prednisolone) for 3-5 days
• IOP check at 1 hour post-procedure (risk of IOP spike)

Efficacy:

• Success rate: 70-80% achieve ≥20% IOP reduction
• Effect: IOP reduction of 20-30% (typically 6-8 mmHg drop)
• Onset: Gradual over 4-6 weeks (peak effect at 6-8 weeks)
• Duration: 3-5 years average (range 1-10+ years)
• Repeatability: Can be repeated (success rate slightly lower ~60-70%)

Advantages:

• No daily medication burden (improved compliance)
• Avoids systemic side effects of drops
• Avoids ocular surface disease from preservatives
• Cost-effective
• Repeatable

Complications (Rare):

• Transient IOP spike (5-10%, usually resolves in hours)
• Mild inflammation (1-2 days)
• Peripheral anterior synechiae (less than 1%)
• Failure (20-30% non-responders)

Contraindications:

• Angle closure or very narrow angles (unable to visualize TM)
• Uveitic glaucoma (active inflammation)
• Neovascular glaucoma (abnormal angle vessels)

Argon Laser Trabeculoplasty (ALT)

• Older technique (largely replaced by SLT)
• Uses 488/514 nm argon laser (continuous wave)
• Mechanism: Thermal coagulation creates scarring, which contracts and "stretches" adjacent TM (increasing pore size)
• Limitations:
  • Non-selective tissue destruction
  • Cannot be safely repeated (causes scarring)
  • Slightly higher complication rate
• Still used in some centers (lower equipment cost)

---

Second-Line: Medical Therapy (Topical Medications)

When SLT unavailable, unsuitable, or insufficient, topical medications are used.

Principles:

• Start with monotherapy (single agent)
• If inadequate, add second agent (adjunctive therapy)
• Fixed-combination drops preferred over two separate bottles (better compliance)
• Maximize one class before adding another
• Instruct patient on proper instillation technique:
  • "Punctal Occlusion: Close eyelids and apply pressure to inner corner (punctum) for 1-2 minutes after drop"
  • Reduces systemic absorption via nasolacrimal duct
  • Especially important for beta-blockers (prevent bradycardia, bronchospasm)

1. Prostaglandin Analogues (PGAs)

Agents:

• Latanoprost (Xalatan®) 0.005%
• Travoprost (Travatan®) 0.004%
• Bimatoprost (Lumigan®) 0.01% or 0.03%
• Tafluprost (Saflutan®) 0.0015% - preservative-free

Mechanism:

• Increases uveoscleral outflow (non-conventional pathway)
• Remodels ciliary muscle and extracellular matrix

Dosing: Once daily at night (optimal timing)

Efficacy: 25-35% IOP reduction (most potent class)

Side Effects:

• Ocular:
  • Conjunctival hyperemia (red eye) - 15-45%
  • Hypertrichosis (longer, thicker eyelashes)
  • Iris hyperpigmentation (brown discoloration, especially hazel/green eyes) - permanent
  • Periorbital skin hyperpigmentation (reversible)
  • "Prostaglandin-associated periorbitopathy (PAPS): Deepening of eyelid sulcus, enophthalmos (sunken eye)"
  • Cystoid macular edema (rare, mainly in aphakic/pseudophakic eyes)
  • Reactivation of herpes simplex keratitis (caution in herpetic eye disease)
• Systemic: Minimal (very low systemic absorption)

Contraindications:

• Active uveitis (may worsen inflammation)
• Pregnancy (Category C—avoid)
• Caution in history of herpetic keratitis

Clinical Pearls:

• Most effective class, best adherence (once-daily dosing)
• Warn about cosmetic changes (especially iris color change—permanent)
• Hypertrichosis sometimes seen as cosmetic benefit (Latisse® = bimatoprost marketed for eyelash growth)

2. Beta-Blockers

Agents:

• Timolol (Timoptol®) 0.25%, 0.5% - non-selective
• Betaxolol (Betoptic®) 0.5% - β1-selective (cardioselective)
• Levobunolol (Betagan®) 0.5% - non-selective
• Carteolol 1-2% - non-selective with intrinsic sympathomimetic activity

Mechanism: Reduce aqueous production (via ciliary body β2-receptors)

Dosing: Twice daily (BD) or once daily (timolol gel-forming solution)

Efficacy: 20-25% IOP reduction

Side Effects:

• Ocular: Dry eyes, superficial punctate keratitis, reduced corneal sensitivity
• Systemic (due to nasolacrimal absorption):
  • "Respiratory: Bronchospasm, worsening of asthma/COPD (especially non-selective) [12]"
  • "Cardiovascular: Bradycardia, heart block, hypotension, worsening heart failure"
  • "CNS: Fatigue, depression, confusion, impotence, reduced exercise tolerance"
  • "Metabolic: Masking of hypoglycemia symptoms (in diabetics on insulin)"

Contraindications (ABSOLUTE for non-selective):

• Asthma, COPD with bronchospasm
• Sinus bradycardia, 2nd/3rd degree heart block
• Decompensated heart failure

Contraindications (RELATIVE):

• Diabetes on insulin (masks hypoglycemia warning signs)
• Depression
• Myasthenia gravis

Clinical Pearls:

• Betaxolol (β1-selective) safer in mild COPD, but still contraindicated in asthma
• Always ask about respiratory disease before prescribing
• Teach punctal occlusion technique (critical for beta-blockers)
• Generic available (low cost)

3. Carbonic Anhydrase Inhibitors (CAIs)

Topical Agents:

• Dorzolamide (Trusopt®) 2%
• Brinzolamide (Azopt®) 1%

Mechanism: Inhibit carbonic anhydrase in ciliary epithelium → reduces aqueous production

Dosing: 2-3 times daily (TDS or BD)

Efficacy: 15-20% IOP reduction (less potent than PGAs or beta-blockers)

Side Effects:

• Ocular: Burning/stinging on instillation (common with dorzolamide), bitter taste (via nasolacrimal drainage), allergic blepharoconjunctivitis, superficial punctate keratitis
• Systemic: Minimal (sulfonamide derivative—caution in sulfa allergy)

Combination Products:

• Cosopt®: Dorzolamide/timolol (BD dosing)
• Azarga®: Brinzolamide/timolol (BD dosing)
• Improved compliance vs. two separate bottles

Clinical Pearls:

• Useful as adjunctive therapy (rarely used as monotherapy)
• Brinzolamide better tolerated than dorzolamide (less stinging)
• Preservative-free formulations available (for ocular surface disease)

4. Alpha-2 Adrenergic Agonists

Agents:

• Brimonidine (Alphagan®) 0.1%, 0.15%, 0.2%
• Apraclonidine (Iopidine®) 0.5%, 1% - rarely used chronically (high allergy rate)

Mechanism:

• Reduce aqueous production (via α2-receptors on ciliary epithelium)
• Increase uveoscleral outflow
• Possible neuroprotective effect (theoretical)

Dosing: 2-3 times daily (BD or TDS)

Efficacy: 20-25% IOP reduction

Side Effects:

• Ocular: Allergic conjunctivitis (10-15% with chronic use), conjunctival blanching (vasoconstriction), dry eyes
• Systemic: Fatigue, drowsiness, dry mouth, hypotension, bradycardia (especially in elderly or low body weight)
• Pediatric: CNS depression (contraindicated in children less than 2 years)

Contraindications:

• Infants and young children (less than 2 years)
• Patients on MAO inhibitors
• Caution in cardiovascular disease

Clinical Pearls:

• High rate of allergic reactions (follicular conjunctivitis) limits long-term use
• Lower concentration (0.1%, 0.15%) better tolerated than 0.2%
• Useful as adjunctive therapy

5. Cholinergic Agonists (Miotics)

Agent:

• Pilocarpine 0.5-4%

Mechanism: Contracts ciliary muscle → opens trabecular meshwork → increases conventional outflow

Dosing: 4 times daily (QID) - poor compliance

Efficacy: 20-25% IOP reduction

Side Effects:

• Ocular: Miosis (small pupil), dimming of vision, induced myopia (ciliary spasm), brow ache, increased risk of retinal detachment (especially young myopes)
• Systemic: Rare with topical use (sweating, salivation, GI upset if absorbed)

Current Use: Rarely used (due to side effects and QID dosing)

• May be used in pseudophakic patients (no accommodation issue)
• Angle-closure glaucoma (to pull peripheral iris away from angle)

---

Third-Line: Surgical Intervention

Surgery considered when:

• Maximal medical therapy insufficient to achieve target IOP
• Poor compliance with medications
• Intolerable side effects from medications
• Patient preference for surgical solution
• Advanced disease requiring aggressive IOP lowering
• SLT and medications both failed

1. Trabeculectomy ("Trab")

Principle: Create controlled fistula from anterior chamber to subconjunctival space, allowing aqueous to bypass trabecular meshwork

Procedure:

1. Partial-thickness scleral flap created
2. Block of deep scleral tissue + trabecular meshwork removed ("trabeculectomy")
3. Peripheral iridectomy performed (prevent iris plugging ostium)
4. Scleral flap sutured loosely (allows flow)
5. Conjunctiva closed (forms subconjunctival bleb)
6. Antimetabolites (Mitomycin-C or 5-fluorouracil) applied to prevent scarring

Success Rate: 70-90% achieve target IOP at 1 year; 50-70% at 5 years

Efficacy: Can achieve very low IOP (often 10-14 mmHg or lower)

Complications:

• Early:
  • Hypotony (over-filtration, IOP too low) → choroidal effusion, hypotony maculopathy
  • Hyphema (blood in anterior chamber)
  • Shallow/flat anterior chamber
  • Choroidal hemorrhage (rare, less than 1%)
• Late:
  • "Bleb-related: Bleb leak, dysesthesia (cosmetically prominent bleb), blebitis (infection), endophthalmitis (1-5% lifetime risk)"
  • "Bleb failure: Scarring, encapsulation (may require bleb needling/revision)"
  • Cataract (accelerated formation)
• Visual: Reduced vision (10-20%), wipe-out (sudden loss of central vision, rare but devastating in advanced glaucoma)

Post-operative Management:

• Intensive topical steroids (prednisolone 1% hourly initially, tapered over months)
• Monitor for complications
• May require suture lysis or needling to enhance filtration
• Lifelong bleb monitoring (infection risk)

Clinical Pearls:

• Gold standard for decades (most established procedure)
• Risk of sight-threatening complications (weigh risks vs. benefits)
• Requires meticulous post-operative care
• Antimetabolites essential for success (prevent scarring) but increase complication risk

2. Glaucoma Drainage Devices (Tube Shunts)

Types:

• Non-valved: Molteno, Baerveldt (require ligature to limit early flow)
• Valved: Ahmed (pressure-sensitive valve)

Principle: Silicone tube inserted into anterior chamber, drains to equatorial plate, forms encapsulated bleb posteriorly

Indications:

• Failed trabeculectomy
• High-risk eyes (uveitic, neovascular, aphakic, previous surgery)
• Secondary glaucomas

Success Rate: 70-85% at 1 year

Complications:

• Tube erosion, malposition, corneal decompensation
• Hypotony (non-valved during early period)
• Elevated IOP (hypertensive phase 4-8 weeks post-op)
• Endophthalmitis, diplopia (restrictive strabismus)

Comparison to Trab: Tube Versus Trabeculectomy (TVT) Study showed similar efficacy; tubes may have lower failure rate in high-risk eyes but higher complication rate overall

3. Minimally Invasive Glaucoma Surgery (MIGS)

Rationale: Ab interno (from inside eye) procedures, minimal tissue disruption, faster recovery, fewer complications (but more modest IOP reduction)

Devices/Procedures:

A. Trabecular Bypass Stents:

• iStent® / iStent inject®: Titanium micro-stent inserted into Schlemm's canal (bypasses TM)
• Hydrus®: Scaffold device in Schlemm's canal
• Typically performed during cataract surgery (combined procedure)
• Efficacy: IOP reduction ~15-20% (modest)
• Reduces medication burden

B. Suprachoroidal Shunts:

• CyPass® (withdrawn): Drained to suprachoroidal space
• Moderate IOP reduction

C. Subconjunctival Procedures:

• XEN Gel Stent®: Soft gel tube from AC to subconjunctival space (minimally invasive trabeculectomy)
• PreserFlo MicroShunt®: Similar concept
• Efficacy: IOP reduction similar to trabeculectomy but fewer complications
• May still require antimetabolites

D. Endocyclophotocoagulation (ECP):

• Laser ablation of ciliary processes (reduces production)
• Performed during cataract surgery or standalone
• Useful in refractory glaucoma

Indications: Mild-moderate POAG (not suitable for advanced disease requiring aggressive IOP lowering)

Advantages: Faster recovery, fewer complications, preserves conjunctiva for future trabeculectomy

Limitations: More modest IOP reduction, long-term data still emerging, not suitable for advanced glaucoma

4. Cyclodestructive Procedures

Principle: Destroy ciliary body (site of aqueous production) to reduce IOP

Techniques:

• Transscleral Cyclophotocoagulation (TCP): Diode laser applied externally
• Micropulse TCP: Pulsed delivery (less tissue destruction, fewer complications)
• Cyclocryotherapy: Freezing (older technique, rarely used)

Indications:

• Refractory glaucoma (failed trab, tubes)
• Poor visual potential
• Painful blind eye (reduce IOP to relieve pain)

Efficacy: Variable (50-70% achieve IOP reduction), often requires repeat treatment

Complications: Hypotony, phthisis (shrunken eye), vision loss, inflammation, pain

Role: Last resort (when other options exhausted) or for palliation

---

9. Monitoring and Follow-Up

Newly Diagnosed / Initiating Treatment:

• Review at 4-6 weeks post-SLT or post-medication initiation
• Assess IOP response, side effects, compliance
• Visual fields at baseline (×2) and 6-12 months
• OCT at baseline and 6-12 months

Stable Disease (Controlled on Treatment):

• IOP check every 3-6 months
• Visual field testing every 6-12 months
• OCT every 12 months
• Optic disc assessment (clinical or photography) annually
• Assess compliance, medication side effects

Unstable / Progressing Disease:

• More frequent monitoring (IOP every 1-3 months)
• Visual fields every 3-6 months
• OCT every 6 months
• Reassess target IOP (may need more aggressive lowering)
• Consider surgical intervention

Criteria for Progression:

• Structural:
  • Optic disc change (enlargement of cup, new notching, disc hemorrhage)
  • RNFL thinning on OCT (beyond measurement variability)
• Functional:
  • Visual field worsening on trend analysis (GPA)
  • Sustained MD decline >2 dB
  • Expansion or deepening of scotomas
• IOP: Failure to achieve target despite treatment

Post-Surgical:

• Frequent early visits (day 1, week 1, weeks 2-4, etc.)
• Long-term: Every 3-6 months (lifelong monitoring)
• Monitor for bleb-related complications

---

10. Complications and Prognosis

Complications of Disease

Visual Loss:

• Progressive, irreversible visual field constriction
• Legal blindness (visual field less than 20° or acuity less than 6/60 in better eye)
• End-stage: Complete blindness

Functional Impairment:

• Difficulty with mobility, driving, reading, activities of daily living
• Increased risk of falls and fractures (especially elderly)
• Reduced quality of life
• Depression and social isolation

Driving:

• DVLA (UK) standards:
  • "Group 1 (cars, motorcycles): Minimum 120° horizontal field, no significant defects within central 20°"
  • "Group 2 (lorries, buses): More stringent (effectively precludes most moderate-advanced glaucoma)"
• Must notify DVLA if both eyes affected or field loss significant
• Periodic field testing required

Employment: May affect occupations requiring good peripheral vision (pilots, professional drivers, etc.)

Prognosis

Natural History (Untreated):

• Slow progression over 15-25 years from diagnosis to blindness (average)
• Highly variable (some fast progressors lose significant vision in 5-10 years)
• Approximately 10-15% of untreated POAG patients become bilaterally blind

With Treatment:

• Most patients retain useful vision for life if diagnosed early and adherent to treatment
• Advanced Glaucoma Intervention Study (AGIS): IOP less than 18 mmHg associated with minimal progression [37]
• Collaborative Normal-Tension Glaucoma Study (CNTGS): 30% IOP reduction slowed progression by 50% [38]
• Early Manifest Glaucoma Trial (EMGT): Treating early glaucoma reduces progression risk by ~50% [39]

Factors Affecting Prognosis:

• Good:
  • Early diagnosis (minimal damage at baseline)
  • Good IOP control
  • Slow progression rate
  • Adherence to treatment
  • Younger age (longer time for progression before functional impairment)
• Poor:
  • Advanced damage at diagnosis
  • Uncontrolled IOP
  • Fast progression
  • Non-adherence
  • Monocular (one-eyed patient)
  • African ancestry (more aggressive disease)
  • Thin CCT
  • Disc hemorrhages (marker of instability)

Life Expectancy Considerations:

• Slowly progressing glaucoma in elderly patients may never cause functional disability within lifetime
• Treatment burden (daily drops, visits, side effects, cost) must be balanced against risk
• Shared decision-making critical

---

11. Patient Education and Adherence

Adherence Challenges

Poor Adherence is Common:

• Studies show only 50-70% of glaucoma patients take drops as prescribed
• Factors:
  • Asymptomatic disease (no immediate consequence of missing doses)
  • Complex regimen (multiple drops, multiple times daily)
  • Side effects (stinging, red eyes, systemic effects)
  • Forgetfulness
  • Cost (especially if multiple medications)
  • Difficulty with administration (elderly, arthritis, tremor)
  • Lack of understanding of disease seriousness

Strategies to Improve Adherence:

• Education: Explain irreversible nature of vision loss, importance of prevention
• Simplify Regimen: Once-daily drops preferred, fixed-combination drops
• Address Side Effects: Switch medications if intolerable
• Reminders: Pill boxes, smartphone apps, link to daily routines (brushing teeth)
• Involve Family: Caregivers can assist with administration
• Consider SLT: Removes daily medication burden entirely
• Regular Follow-up: Reinforces importance, monitors adherence

Patient Education Key Points

What is Glaucoma?:

• "Glaucoma is damage to the optic nerve (the cable connecting your eye to your brain) caused by pressure inside the eye being too high."
• "Vision lost from glaucoma is gone forever—we can't bring it back. Treatment is about saving what you have left."

Why Can't I Feel It?:

• "Glaucoma damages your peripheral (side) vision first. Your brain fills in the gaps, so you don't notice until a lot of damage has occurred."
• "By the time you notice tunnel vision, you've already lost 90% of the nerve."

Treatment:

• "The eye drops/laser don't improve your vision—they stop it from getting worse."
• "If you stop treatment, the pressure goes back up and the nerve damage continues."

Analogy for Aqueous Dynamics:

• "Your eye is like a sink. There's a tap (making fluid) and a drain (draining fluid). In glaucoma, the drain gets clogged. The tap keeps running, so pressure builds up and squashes the nerve."

Drop Technique:

• "Tilt your head back, pull down lower lid, look up, squeeze one drop into the pocket."
• "Close your eyes and press on the inner corner (near nose) for 1-2 minutes—this stops the drop draining down your throat and causing side effects."

Laser (SLT):

• "It's a gentle 'clean-out' of the drain using light. Takes 10-15 minutes, is painless, and means you might not need daily drops."

Surgery (Trabeculectomy):

• "We create a new drainage channel to bypass the clogged drain. It's a bigger operation with risks, but it can lower the pressure more than drops or laser."

Driving:

• "If glaucoma affects your side vision significantly, you must tell the DVLA. They may ask for a field test to check if you're safe to drive."

---

12. Special Populations

Normal-Tension Glaucoma (NTG)

• Optic nerve damage and visual field loss typical of glaucoma, but IOP consistently less than 21 mmHg
• Represents 30-40% of POAG in Caucasians, up to 90% in some Asian populations
• Pathophysiology: Multifactorial
  • Vascular insufficiency (low ocular perfusion pressure)
  • Nocturnal hypotension
  • Vasospasm (migraine, Raynaud's)
  • Structurally weak lamina cribrosa
  • Autoimmune factors
• Evaluation: Rule out other causes (past angle closure, uveitis, steroid use, neurological disease mimicking glaucomatous field loss)
• Management:
  • IOP lowering still beneficial (target 30% reduction, often less than 12-15 mmHg)
  • Address vascular risk factors (avoid nocturnal hypotension, treat sleep apnea)
  • CNTGS showed 30% IOP reduction reduced progression [38]

Juvenile-Onset POAG

• Onset before age 40 (often 20s-30s)
• More aggressive course
• Often higher IOP (>30 mmHg)
• Strong genetic component (MYOC mutations in ~10%)
• Often requires surgery earlier in disease course

Ocular Hypertension (OHT)

• IOP >21 mmHg on multiple occasions
• Normal optic disc and visual fields (no evidence of glaucomatous damage)
• Risk of Conversion: OHTS showed 10% convert to POAG over 5 years if untreated
• Treatment Indications (NICE NG81):
  • "IOP ≥24 mmHg: Offer treatment"
  • "IOP 22-23 mmHg: Consider treatment if high-risk features:"
    • Cup:disc ratio ≥0.7
    • Thin CCT (less than 555 μm)
    • Age >60
    • Family history
• Treatment: SLT preferred (LiGHT trial included OHT patients)

Pregnancy

• IOP Changes: Physiological decrease in IOP during pregnancy (10-20% reduction)—hormonal and hemodynamic changes
• Medication Safety:
  • "Prostaglandin Analogues: Category C—avoid (uterine contractions in animal studies)"
  • "Beta-blockers: Category C—use if benefit outweighs risk (fetal bradycardia, growth restriction risk)"
  • "Brimonidine: Category B—relatively safe"
  • "CAIs (topical): Category C—caution (sulfonamide derivative)"
• Management: Consider stopping treatment during pregnancy if disease stable and IOP controlled (physiological IOP reduction may suffice)
• Post-partum: Restart treatment (IOP rises back to baseline)

Pediatric Glaucoma

• Primary Congenital Glaucoma: Distinct entity (developmental anomaly of angle)
  • "Classic triad: Epiphora (tearing), photophobia, blepharospasm"
  • Buphthalmos (enlarged globe)—cornea >12 mm diameter
  • Haab's striae (breaks in Descemet's membrane)
  • Requires surgical intervention (goniotomy, trabeculotomy)
• Juvenile Glaucoma: Presents in older children/teenagers, similar to adult POAG

---

13. Evidence Base and Guidelines

Key Guidelines

Landmark Trials

1. LiGHT Trial (Lancet 2019)

• Design: Multicenter RCT, 718 patients with newly diagnosed OHT or POAG
• Intervention: SLT vs. topical medication (latanoprost)
• Results (36-month follow-up):
  • "Health-related quality of life better with SLT (EQ-5D: 0.91 vs. 0.89, p=0.008)"
  • "Disease progression: 11.4% (SLT) vs. 19.5% (drops), p=0.004"
  • "Drop-free survival: 93% vs. 0%"
  • "Cost saving: £500-700 per patient"
• Impact: Changed practice—NICE now recommends SLT first-line [7]

2. Ocular Hypertension Treatment Study (OHTS)

• Design: Multicenter RCT, 1,636 OHT patients
• Intervention: Topical medication vs. observation
• Results:
  • 5-year conversion to glaucoma: 4.4% (treatment) vs. 9.5% (observation)
  • Treatment reduced risk by 50%
  • "Identified risk factors: High IOP, thin CCT, large C:D ratio, age"
• Impact: Established benefit of treating high-risk OHT [8]

3. Collaborative Normal-Tension Glaucoma Study (CNTGS)

• Design: Multicenter RCT, NTG patients
• Intervention: 30% IOP reduction vs. no treatment
• Results: Treatment reduced progression by 50% (but still ~30% progressed despite treatment)
• Impact: Even "normal" IOP benefits from lowering in NTG [38]

4. Advanced Glaucoma Intervention Study (AGIS)

• Design: Multicenter RCT, advanced POAG
• Intervention: Trabeculectomy vs. ALT
• Results: IOP less than 18 mmHg throughout follow-up associated with no progression
• Impact: "IOP less than 18 mmHg" target for advanced disease [37]

5. Early Manifest Glaucoma Trial (EMGT)

• Design: RCT, newly diagnosed glaucoma
• Intervention: ALT + betaxolol vs. observation
• Results: Treatment reduced progression by 50%; identified risk factors (high IOP, bilateral disc hemorrhages, pseudoexfoliation)
• Impact: Benefits of early treatment [39]

6. Tube Versus Trabeculectomy (TVT) Study

• Design: RCT, Baerveldt tube vs. trabeculectomy (MMC) in high-risk eyes
• Results: Similar efficacy; tube lower failure rate but higher complications (reoperation for complications 30% vs. 19%)
• Impact: Tubes are viable alternative in high-risk eyes [43]

---

14. Examination Focus

Common OSCE/Clinical Exam Scenarios

Station 1: Fundoscopy

• Task: "Examine this patient's optic discs and comment on your findings."
• Findings: Increased C:D ratio, violation of ISNT rule, disc hemorrhage
• Diagnosis: "This patient has signs of glaucomatous optic neuropathy."
• Management: "I would measure IOP, perform gonioscopy to exclude angle closure, assess visual fields, and obtain OCT imaging."

Station 2: Visual Field Interpretation

• Task: "Interpret this visual field."
• Findings: Arcuate scotoma respecting horizontal meridian, elevated PSD, normal MD
• Diagnosis: "Early glaucomatous field defect."

Station 3: Patient Counseling (Drops)

• Task: "Counsel this patient on starting latanoprost eye drops."
• Key Points:
  • Explain glaucoma (irreversible, preventative treatment)
  • "Dosing: Once at night"
  • "Technique: One drop, punctal occlusion"
  • "Side effects: Eyelash growth, iris darkening (permanent)"
  • Importance of adherence

Station 4: Emergency Scenario

• Presentation: "68-year-old with acute severe eye pain, vomiting, seeing halos."
• Diagnosis: Acute Angle Closure Glaucoma (NOT POAG—different entity)
• Action: Emergency—immediate IOP lowering, pilocarpine, laser iridotomy

Common Viva Questions

Q1: What is the triad of glaucoma? A: Elevated IOP + Optic disc cupping + Visual field loss (though any component can be absent in variants)

Q2: What is the ISNT rule? A: Normal neuroretinal rim thickness: Inferior > Superior > Nasal > Temporal. Glaucoma violates this rule.

Q3: A patient with asthma presents with newly diagnosed glaucoma. Which topical medication should be avoided? A: Beta-blockers (timolol, levobunolol)—risk of bronchospasm due to systemic absorption.

Q4: What does the LiGHT trial tell us? A: Selective Laser Trabeculoplasty (SLT) is superior to eye drops (latanoprost) as first-line treatment for POAG and OHT, with better outcomes, quality of life, and cost-effectiveness.

Q5: What is normal-tension glaucoma? A: Glaucomatous optic neuropathy with characteristic disc changes and visual field loss, but IOP consistently less than 21 mmHg. Likely vascular etiology. Still benefits from IOP lowering (30% reduction target).

Q6: What factors affect Goldmann applanation tonometry accuracy? A: Corneal thickness (thick → overestimate, thin → underestimate), high astigmatism, corneal edema, scarring.

Q7: What is the significance of a disc hemorrhage? A: Marker of active glaucoma progression (Drance hemorrhage). Associated with worse prognosis. Indicates need for more aggressive IOP lowering.

Q8: Describe the aqueous outflow pathways. A:

• Conventional (80-90%): Trabecular meshwork → Schlemm's canal → Collector channels → Episcleral veins (blocked in POAG)
• Unconventional (10-20%): Uveoscleral pathway through ciliary muscle (enhanced by prostaglandins)

Q9: What are the indications for trabeculectomy? A: Failure of medical therapy and laser to achieve target IOP, advanced disease requiring aggressive lowering, intolerable medication side effects, patient preference.

Q10: What is the mechanism of selective laser trabeculoplasty? A: 532 nm laser selectively targets pigmented TM cells, inducing biological response (cytokine release, macrophage recruitment), remodeling extracellular matrix, reducing outflow resistance.

---

15. Differential Diagnosis

Conditions Mimicking POAG

1. Secondary Open-Angle Glaucomas

• Pseudoexfoliation Glaucoma: White flaky material on lens capsule, TM (higher IOP, faster progression)
• Pigment Dispersion Syndrome: Pigment deposition on corneal endothelium (Krukenberg spindle), TM, iris transillumination defects
• Uveitic Glaucoma: History of inflammation, keratic precipitates, posterior synechiae
• Steroid-Induced Glaucoma: Recent steroid use (topical, oral, inhaled, intra-articular)
• Traumatic Glaucoma: Angle recession from blunt trauma

2. Angle-Closure Glaucoma

• Acute: Severe pain, nausea, vomiting, halos—EMERGENCY
• Chronic: Gradual angle closure, peripheral anterior synechiae on gonioscopy
• Distinguishing feature: Narrow/closed angle on gonioscopy vs. open in POAG

3. Normal-Tension Glaucoma (NTG)

• Subset of POAG with IOP less than 21 mmHg
• Rule out past angle closure, neurological causes

4. Other Optic Neuropathies

• Anterior Ischemic Optic Neuropathy (AION): Sudden vision loss, pale swollen disc, altitudinal field defect
• Optic Neuritis: Pain with eye movement, RAPD, central scotoma, younger age (MS association)
• Compressive Lesions: Pituitary adenoma (bitemporal hemianopia), optic nerve sheath meningioma
• Toxic/Nutritional: Methanol, tobacco-alcohol amblyopia (central scotoma, not peripheral)
• Hereditary: Leber's hereditary optic neuropathy (young males, sudden bilateral vision loss)

5. Retinal Disease Mimicking Field Loss

• Retinal Detachment: Peripheral field defect corresponding to detached area, visible on fundoscopy
• Retinitis Pigmentosa: Night blindness, bone-spicule pigmentation, waxy disc pallor

6. Neurological Causes

• Chiasmal lesions: Bitemporal hemianopia (pituitary tumor)
• Post-chiasmal: Homonymous hemianopia (stroke, tumor)—field defect respects vertical meridian, not horizontal

---

16. Recent Advances and Future Directions

Neuroprotection:

• IOP-independent strategies to prevent RGC death
• Agents under investigation: Brimonidine (possible neuroprotective effect beyond IOP lowering), citicoline, Ginkgo biloba, NMDA antagonists, neurotrophic factors
• No proven neuroprotective agent currently available

Sustained-Release Drug Delivery:

• Bimatoprost Implant (Durysta®): Biodegradable intracameral implant releasing bimatoprost for 4-6 months
• Travoprost Implant: In development
• Eliminates adherence issues

Gene Therapy:

• Viral vector delivery of genes to enhance TM function or protect RGCs
• Early-phase trials

Stem Cell Therapy:

• Trabecular meshwork stem cells to regenerate dysfunctional TM
• RGC replacement (very experimental—optic nerve regeneration major challenge)

Artificial Intelligence:

• Deep learning algorithms for detecting glaucomatous changes on OCT, visual fields, fundus photos
• Predict progression
• Telemedicine/remote screening

Novel Surgical Techniques:

• Continued evolution of MIGS devices
• Ab-interno canaloplasty (360° catheterization of Schlemm's canal)

Biomarkers:

• Blood or aqueous humor biomarkers to predict disease onset, progression
• Genetic testing for high-risk individuals (polygenic risk scores)

Home Monitoring:

• Self-tonometry devices for home IOP monitoring
• Home visual field testing (tablet-based)
• Continuous IOP monitoring (contact lens sensors—investigational)

---

17. Key Takeaways

1. POAG is the "Silent Thief of Sight": Asymptomatic until advanced; early detection relies on screening.

2. IOP is key modifiable risk factor: Every 1 mmHg matters; lowering IOP slows progression even in NTG.

3. SLT is now first-line (NICE 2022): Better outcomes and quality of life than drops.

4. Gonioscopy is essential: Must confirm open angle to diagnose POAG (vs. angle closure).

5. OCT detects damage years before fields: Structural changes precede functional loss.

6. Target IOP is individualized: Based on severity, progression, life expectancy (typically 20-30% reduction).

7. Vision loss is irreversible: Treatment is purely preventative—saving remaining vision.

8. Adherence is critical: 50% non-adherence rate; simplify regimen, educate patient.

9. Surgery when medical therapy fails: Trabeculectomy remains gold standard for refractory disease.

10. Lifelong monitoring required: Glaucoma is chronic; progression can occur even with treatment.

---

18. References

Primary Sources

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267. doi:10.1136/bjo.2005.081224

2. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901-1911. doi:10.1001/jama.2014.3192

3. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. doi:10.1016/j.ophtha.2014.05.013

4. Heijl A, Bengtsson B, Hyman L, Leske MC. Natural history of open-angle glaucoma. Ophthalmology. 2009;116(12):2271-2276. doi:10.1016/j.ophtha.2009.06.042

5. Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4:52-59. doi:10.2174/1874364101004010052

6. Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res. 2009;88(4):648-655. doi:10.1016/j.exer.2009.02.007

7. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505-1516. doi:10.1016/S0140-6736(18)32213-X

8. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714-720. doi:10.1001/archopht.120.6.714

9. Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2001;108(10):1779-1788. doi:10.1016/s0161-6420(01)00760-6

10. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279. doi:10.1001/archopht.120.10.1268

11. Jonas JB, Budde WM, Panda-Jonas S. Ophthalmoscopic evaluation of the optic nerve head. Surv Ophthalmol. 1999;43(4):293-320. doi:10.1016/s0039-6257(98)00049-6

12. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122(7):957-965. doi:10.1001/archopht.122.7.957

13. Kapetanakis VV, Chan MPY, Foster PJ, et al. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016;100(1):86-93. doi:10.1136/bjophthalmol-2015-307223

14. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532-538. doi:10.1001/archopht.122.4.532

15. Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol. 1994;112(6):821-829. doi:10.1001/archopht.1994.01090180121046

16. Racette L, Wilson MR, Zangwill LM, et al. Primary open-angle glaucoma in blacks: a review. Surv Ophthalmol. 2003;48(3):295-313. doi:10.1016/s0039-6257(03)00028-6

17. Varma R, Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111(8):1439-1448. doi:10.1016/j.ophtha.2004.01.025

18. Kim CS, Seong GJ, Lee NH, et al. Prevalence of primary open-angle glaucoma in central South Korea the Namil study. Ophthalmology. 2011;118(6):1024-1030. doi:10.1016/j.ophtha.2010.10.016

19. Stone EM, Fingert JH, Alward WLM, et al. Identification of a gene that causes primary open angle glaucoma. Science. 1997;275(5300):668-670. doi:10.1126/science.275.5300.668

20. Choquet H, Wiggs JL, Khawaja AP. Clinical implications of recent advances in primary open-angle glaucoma genetics. Eye (Lond). 2020;34(1):29-39. doi:10.1038/s41433-019-0632-7

21. Leske MC, Wu SY, Hennis A, et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008;115(1):85-93. doi:10.1016/j.ophtha.2007.03.017

22. Marcus MW, de Vries MM, Junoy Montolio FG, Jansonius NM. Myopia as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. Ophthalmology. 2011;118(10):1989-1994. doi:10.1016/j.ophtha.2011.03.012

23. Brubaker RF. Flow of aqueous humor in humans. Invest Ophthalmol Vis Sci. 1991;32(13):3145-3166.

24. Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol. 1963;69:783-801. doi:10.1001/archopht.1963.00960040789022

25. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53 Suppl1:S107-S120. doi:10.1016/j.survophthal.2008.08.010

26. Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res. 2009;88(4):752-759. doi:10.1016/j.exer.2008.10.004

27. Izzotti A, Saccà SC, Cartiglia C, De Flora S. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med. 2003;114(8):638-646. doi:10.1016/s0002-9343(03)00114-1

28. Burgoyne CF, Downs JC, Bellezza AJ, et al. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res. 2005;24(1):39-73. doi:10.1016/j.preteyeres.2004.06.001

29. Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;21(4):359-393. doi:10.1016/s1350-9462(02)00008-3

30. Quigley HA, Nickells RW, Kerrigan LA, et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36(5):774-786.

31. Tezel G, Wax MB. The immune system and glaucoma. Curr Opin Ophthalmol. 2004;15(2):80-84. doi:10.1097/00055735-200404000-00003

32. Hood DC, Raza AS, de Moraes CG, et al. Glaucomatous damage of the macula. Prog Retin Eye Res. 2013;32:1-21. doi:10.1016/j.preteyeres.2012.08.003

33. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(11):1965-1972. doi:10.1016/j.ophtha.2007.03.016

34. Drance SM. Disc hemorrhages in the glaucomas. Surv Ophthalmol. 1989;33(5):331-337. doi:10.1016/0039-6257(89)90010-6

35. Ehlers N, Bramsen T, Sperling S. Applanation tonometry and central corneal thickness. Acta Ophthalmol (Copenh). 1975;53(1):34-43. doi:10.1111/j.1755-3768.1975.tb01135.x

36. Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995;60(4):359-371. doi:10.1016/s0014-4835(05)80093-4

37. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440. doi:10.1016/s0002-9394(00)00538-9

38. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4):487-497. doi:10.1016/s0002-9394(98)00223-2

39. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279. doi:10.1001/archopht.120.10.1268

40. National Institute for Health and Care Excellence. Glaucoma: diagnosis and management. NICE guideline [NG81]. Published January 2017. Updated November 2022. https://www.nice.org.uk/guidance/ng81

41. Prum BE Jr, Rosenberg LF, Gedde SJ, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern® Guidelines. Ophthalmology. 2016;123(1):P41-P111. doi:10.1016/j.ophtha.2015.10.053

42. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021;105(Suppl 1):1-169. doi:10.1136/bjophthalmol-2021-egsguidelines

43. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153(5):789-803. doi:10.1016/j.ajo.2011.10.026

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines for patient care.